智通财经APP获悉，中共中央政治局委员、国务院副总理刘国中10日到北京大学医学部调研医药创新发 展工作。他强调，要深入学习贯彻习近平总书记关于科技创新和卫生健康工作的重要指示精神，按照党 中央、国务院部署，面向人民生命健康，强化协同攻关和政策落实，加强医药领域基础研究和科技创新 能力建设，积极支持创新药和医疗器械加快发展，为推进健康中国建设提供有力支撑。相关概念股：基 石药业-B(02616)、和誉-B(02256)、和铂医药(02142)、信达生物(01801)。 刘国中还强调，要全链条强化政策保障，落实创新药融资、审评审批、入院使用和多元支付等政策，支 持引导商业健康保险发挥更大作用。要扩大高水平对外开放，深化医药技术国际交流合作，更好增进人 民健康福祉。各有关部门要加强协调、密切配合，健全政企沟通机制，及时回应相关诉求，营造良好发 展环境。 东吴证券指出医药行业三大核心驱动因素：高额BD交易持续落地；头部企业预计2025年扭亏，行业盈 利拐点将至；国内政策环境持续优化。 从资本市场来看：医药板块经历了4年的调整期，2025年至今板块迎来复苏，截至2025年5月30日，医药 生物行业涨跌幅位居申万31个一 ...

Core Viewpoint - The company maintains its profit forecasts for 2025 and 2026 at 0.45 billion and 3.20 billion respectively, while upgrading the target price by 22.8% to HKD 11.3, indicating a potential upside of 17.7% from the current stock price [1] Group 1 - The company presented the latest phase II clinical trial data for the FGFR4 inhibitor Irpagratinib (ABSK-011) combined with Atezolizumab for treating advanced hepatocellular carcinoma patients at the ESMO GI conference [2] - The combination therapy showed impressive efficacy and good safety in both first-line and later-line advanced hepatocellular carcinoma patients, with an objective response rate (ORR) of ≥50% and a median progression-free survival (mPFS) of ≥7 months in the 220mg BID dosage group [3] - In patients previously treated with immune checkpoint inhibitors (ICI), the ORR reached 52.9% with an mPFS of 8.3 months, and the treatment was well-tolerated with a 45.5% incidence of grade 3 or higher treatment-emergent adverse events (TEAE) [3] Group 2 - The company is advancing the domestic registration clinical trial for Irpagratinib, with the first patient dosed on June 16, and the therapy received breakthrough therapy designation from the National Medical Products Administration (NMPA) in May [4] - The company received an $85 million global commercialization option exercise fee from Merck for Pimigatinib (ABSK021), which is expected to significantly benefit the company's 2025 performance [5] - The domestic application for Pimigatinib has been accepted by the NMPA for treating giant cell tumor of tendon sheath, with priority review and breakthrough therapy designations already granted [5]

其 他 报 告 2025年07月10日 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3493 | -0.13 | 1.40 | | 深证成份指数 | 10582 | -0.06 | 1.25 | | 沪深300指数 | 3991 | -0.18 | 1.54 | | 创业板指数 | 2185 | 0.16 | 1.50 | | 上证国债指数 | 226 | 0.00 | 0.16 | | 上证基金指数 | 6945 | -0.04 | 0.16 | | | | 资料来源:同花顺iFinD | | | 海外市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 中国香港恒生指数 | 23892 | -1.06 | -1.52 | | 中国香港国企指数 | 8597 | -1.28 | -1.75 | | 中国台湾加权指数 | 22527 | 0.74 | -0.14 | | 道琼斯指数 | 44241 | ...

及 产 业 医药生物 2025 年 06 月 15 日 本周医药上涨 1.4%，石药/AZ 达 成超 53 亿美元战略合作，和誉匹 米替尼 NDA 获受理 看好 ——医药行业周报（2025/6/9-2025/6/13） 本期投资提示： 业 研 究 / 行 业 点 评 证 券 研 究 报 告 证券分析师 张静含 A0230522080004 zhangjh@swsresearch.com 研究支持 李敏杰 A0230523070006 limj2@swsresearch.com 联系人 李敏杰 (8621)23297818× limj2@swsresearch.com 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 行 业 行 相关研究 《本周医药上涨 1.1%，信达公布 PD- 1/IL-2α-bias 双抗临床数据，万泰九价 HPV 疫苗国内获批上市 ——医药行业周 报（2025/6/2-2025/6/8）》 2025/06/08 《本周医药上涨 2.2%，石药近期或完成 3 笔超 50 亿美元授权交易，11 款创新药同 日获批 ——医药行业周报（2025/5/2 ...

丨 2025年6月12日星期四丨 日前，和誉医药宣布国家药品监督管理局(NMPA)已受理其自主研发的CSF-1R高选择性小分子抑制剂匹 米替尼(pimicotinib)的新药上市申请(NDA)，拟用于需要系统性治疗的腱鞘巨细胞瘤(TGCT)成人患者。 匹米替尼是和誉医药自主研发并进入NDA审批流程的首个项目，已经在多项临床试验中展现出较好的 临床疗效、安全性和耐受性。 NO.2东阳光药递交招股书，拟赴港上市 NO.1中国生物制药宣布将产生一个标志性的重磅对外授权交易 点评：和誉医药匹米替尼申报上市，作为自研首款NDA项目，在腱鞘巨细胞瘤治疗展现潜力，若获批 将填补该领域用药空白，助力企业提升创新竞争力。 6月12日，在美国迈阿密举行的第46届高盛全球医疗健康年会上，中国生物制药资本市场负责人雷鸣透 露，今年以来，对外授权交易已经成为公司重要战略目标之一，目前多项资产具备对外授权潜力，有望 进一步扩大公司"国际化收入"，开启第二增长曲线。近期，这些资产中将会产生一个标志性的重磅对外 授权交易。 6月11日，港交所官网显示，东阳光（600673）药递交了上市申请，中金公司（601995）担任独家保荐 人。东阳光药 ...

Core Viewpoint - Shuyou Shen's subsidiary, Beijitai, has received priority review status from the National Medical Products Administration (NMPA) for its product STSP-0601, which is intended for the treatment of bleeding in adult patients with hemophilia A or B with inhibitors, marking a significant advancement in the drug's approval process [2][3]. Company Developments - Shuyou Shen's stock price surged nearly 190% over a 10-day period, reaching a peak of 34.49 yuan per share, the highest since 2016, following the announcement of the priority review [4]. - The company has 13 major R&D projects in clinical research stages, focusing on unmet therapeutic needs, including monoclonal antibodies and protein drugs [4]. - The capitalized R&D expenditure for STSP-0601 (with inhibitors) is reported at 85.16 million yuan, while for STSP-0601 (without inhibitors) it stands at 10.89 million yuan [3]. Industry Context - The NMPA has also granted priority review status to other companies, including He Yu and Ke Ji Pharmaceuticals, indicating a broader trend in the industry towards expedited drug approvals [5][6]. - He Yu's drug ABSK021 has received multiple recognitions, including breakthrough therapy designation from the NMPA and FDA, and has seen a significant revenue increase due to licensing agreements [6][7]. - Ke Ji's product, a CAR-T cell therapy candidate, has also been recognized by the NMPA and FDA, highlighting the growing focus on innovative cancer treatments within the industry [7].

Core Viewpoint - The announcement of the inclusion of ABSK011 (Ipagotinib) as a breakthrough therapy for advanced hepatocellular carcinoma (HCC) patients who have failed previous treatments marks a significant milestone for the company, indicating its potential to become a "billion-dollar molecule" [1][2][3]. Group 1: Breakthrough Therapy Designation - ABSK011 has been officially designated as a breakthrough therapy for treating FGF19 overexpressing advanced HCC patients who have previously undergone immune checkpoint inhibitors (ICI) and multi-targeted tyrosine kinase inhibitors (mTKI) [1][2]. - This designation follows the earlier approval of Pimicotinib (ABSK021), making ABSK011 the second major product of the company to receive such recognition [1]. Group 2: Clinical Data and Efficacy - Recent clinical data presented at the ESMO conference showed that the 220mg BID dosage of ABSK011 achieved an overall response rate (ORR) of 44.8% in patients with FGF19 overexpressing HCC who had previously been treated with ICIs and mTKIs [3][4]. - The drug demonstrated a median duration of response (mDOR) of 7.4 months and a median progression-free survival (mPFS) of 5.5 months, significantly outperforming existing therapies [3][4]. Group 3: Market Potential and Competitive Advantage - The global liver cancer market is projected to reach approximately $5.3 billion by 2029, with immunotherapy accounting for about 72.2% of the market share [6]. - The company has developed ABSK011 as the first small molecule inhibitor targeting the aberrant activation of the FGF19/FGFR4 signaling pathway, which is expected to provide a differentiated treatment option for HCC patients [2][6]. Group 4: Financial Performance and Investment Value - The company has achieved its first full-year profitability in 2024, generating substantial cash flow and signaling a sustainable growth trajectory [8]. - The management has been actively repurchasing shares, reflecting confidence in the company's future and commitment to returning value to investors [8][9]. Group 5: Stock Market Performance - Following a period of volatility, the company's stock price rebounded significantly, reaching a peak of 8.95 HKD, with a maximum increase of 62.14% over a one-and-a-half-month period [11]. - This price recovery indicates strong market interest and confidence in the company's fundamentals and growth potential [11].

超级赛道大爆发。 今日，港股医药板块全线爆发，昭衍新药最高大涨超16%，泰格医药大涨超12%，绿叶制药一度大涨超11%。 A股创新药板块亦集体走强，海辰药业斩获20cm涨停，众生药业涨停。 消息面上，多家创新药企业宣布将在5月30日至6月3日举办的2025年美国临床肿瘤学会(ASCO)年会上展示创新 药物研究成果。另有分析称，受益于三生制药与辉瑞达成的PD-1/VEGF双抗SSGJ-707全球权益合作的消息催 化，中国创新药企通过技术授权加速融入全球产业链，市场对于国产创新药出海预期被放大。 展望后市，有券商机构认为，目前我国创新药进入成果兑现阶段，研发进展催化较多，有望持续作为2025年医 药板块投资主线。2025年将成为医药行业"三个元年"——收入放量元年（医保谈判后产品加速放量）、盈利跨 越元年（成批企业进入盈利期）、估值抬升元年（支付端改善拉长估值周期）。 全线大爆发 今日，港股开盘后，医药板块全线爆发，恒生医疗保健指数一度大涨超2%。成分股方面，海吉亚医疗一度大 涨超15%，绿叶制药最高涨超11%，康哲药业涨超9%，信达生物涨超7%，亚盛医药-B、金斯瑞生物科技涨超 5%。 与此同时，CRO概念股亦 ...

Group 1: Hong Kong Monetary Environment - The President of the Hong Kong Monetary Authority, Yu Weiwen, stated that the current low interest rate environment for the Hong Kong dollar may not be sustainable, and citizens should consider potential risks when making property, investment, or borrowing decisions [1] - The supply of Hong Kong dollar funds has become abundant due to a significant increase in surplus, but future fluctuations in the Hong Kong dollar exchange rate and interest rates remain uncertain [1] Group 2: Financial Data and Tax Revenue - From January to April, the national general public budget revenue was 80,616 billion yuan, a year-on-year decrease of 0.4%, with tax revenue at 65,556 billion yuan, down 2.1% [3] - The securities transaction stamp duty reached 53.5 billion yuan, marking a year-on-year increase of 57.8% [3] Group 3: Company Developments - Xinhua Insurance is set to participate in the third batch of insurance fund long-term investment reform pilot projects, aiming to increase its allocation to Hong Kong stocks [3] - Zhaoyi Innovation plans to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders and market conditions [4] - CNOOC Defense expects the current shipbuilding market cycle to continue, supported by a balanced global shipyard capacity and demand for fleet renewal [5] - GCL-Poly Energy's assistant vice president indicated that the cost of granular silicon still has room for reduction, with inventory levels remaining low [5] - Nongfu Spring's chairman stated that while the company does not oppose outsourcing, all current products cannot be outsourced due to high dependency on water sources and customized production systems [6] - Hisense Visual released the industry's first "projection-level" home theater equipment, featuring advanced laser projection technology [7] - Huyou-B's CSF-1R inhibitor has been prioritized for review by the National Medical Products Administration for treating TGCT [8] - Shanghai Pharmaceuticals received FDA approval for its rivaroxaban tablets [9] - Tencent launched the first industrial-grade AIGC game content production engine, significantly enhancing game asset generation efficiency [10] Group 4: Financial Performance - ZTO Express reported a 40.9% year-on-year increase in net profit for Q1, reaching 2.0392 billion yuan, with a 19.1% increase in package volume [10] - Gome Retail achieved a profit of 405 million yuan, turning around from a loss, despite a 1.4% decrease in revenue [10] - Huazhu Group's Q1 net profit increased by 35.66% to 894 million yuan, with total revenue rising by 2.22% [11] - Bilibili reported a 24% increase in total revenue for Q1, reaching 7.003 billion yuan, with an adjusted net profit of 362 million yuan, marking a return to profitability [12]

Group 1 - On May 20, 2023, 3SBio announced a licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody "SSGJ-707," granting Pfizer exclusive global rights outside mainland China, with a potential total deal value of $60.5 billion, exceeding 430 billion RMB at current exchange rates [1] - The agreement includes a non-refundable upfront payment of $1.25 billion and up to $4.8 billion in milestone payments for development, regulatory approval, and sales, along with a tiered sales royalty based on product sales in licensed regions [1] - Following the announcement, 3SBio's stock surged over 32%, reaching a market capitalization of 46 billion HKD [1] Group 2 - 3SBio's CEO stated that Pfizer's extensive development experience and international perspective will significantly accelerate the global development and commercialization of SSGJ-707, aiming to provide breakthrough treatment options for patients worldwide [2] - The trend of Chinese innovative drugs entering international markets is expanding, with recent agreements such as CSPC's exclusive licensing deal with Cipla for irinotecan liposome injection in the U.S., which includes a $15 million upfront payment and potential total payments nearing $1.1 billion [2] - Data from Yaozhi shows that in 2024, there were 94 completed outbound licensing transactions for Chinese innovative drugs, totaling $51.9 billion, a 26% year-on-year increase, with 41 transactions in the first quarter of 2025 alone, amounting to $36.9 billion, setting new historical highs [2] Group 3 - On May 12, 2023, former President Trump signed an executive order aimed at reducing prescription drug prices in the U.S., suggesting that prices should decrease by at least 59%, with potential reductions of 80% or 90% in certain cases [3] - Guoyuan Securities believes that the push for drug price reductions in the U.S. will not significantly impact the outbound licensing of innovative drugs from China, citing factors such as low prices for generics and intense competition in the U.S. market [3] - The firm anticipates that the pharmaceutical industry will enter a performance vacuum period starting in May, shifting market focus from earnings to fundamental changes in the industry and companies, maintaining a positive outlook on innovative drugs and international expansion [3] Group 4 - Related concept stocks include Cornerstone Pharmaceuticals, which showcased five innovative products at the AACR annual meeting, including a tri-specific antibody and several ADC molecules [4] - Hanyu Pharmaceuticals announced that its selective small molecule CSF-1R inhibitor has been prioritized for review by the Chinese National Medical Products Administration for treating TGCT patients [4] Group 5 - Hengrui Medicine entered a significant strategic collaboration with AstraZeneca, which includes licensing options for two preclinical immunotherapy projects, with Hengrui receiving $175 million in upfront and milestone payments, plus potential royalties based on net sales [5]